Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

Zelenetz Andrew D.; Brown Jennifer R.; Delgado Julio; Eradat Herbert; Ghia Paolo; Jacob Abraham; Jurczak Wojciech; Loscertales Javier; MacDonald Donald; Morschhauser Franck; De la Serna Javier; Shadman Mazyar; Pocock Christopher; Adewoye Adeboye Henry; Kim Yeonhee; Simpson David; Stilgenbauer Stephan

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

【24h】

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

机译：艾达西单抗联合苯达莫司汀和利妥昔单抗治疗复发/难治性CLL患者的III期随机研究总生存率的最新分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共6页
作者
Zelenetz Andrew D.; Brown Jennifer R.; Delgado Julio; Eradat Herbert; Ghia Paolo; Jacob Abraham; Jurczak Wojciech; Loscertales Javier; MacDonald Donald; Morschhauser Franck; De la Serna Javier; Shadman Mazyar; Pocock Christopher; Adewoye Adeboye Henry; Kim Yeonhee; Simpson David; Stilgenbauer Stephan;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL [J] . Zelenetz Andrew D., Brown Jennifer R., Delgado Julio, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：艾达西单抗联合苯达莫司汀和利妥昔单抗治疗复发/难治性CLL患者的III期随机研究总生存率的最新分析
2. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial [J] . Zelenetz Andrew D., Barrientos Jacqueline C., Brown Jennifer R., The lancet oncology . 2017,第3期

机译：伊德利罗丽金或安慰剂与Bendamustine和Rituximab的复发或难治性慢性淋巴细胞白血病患者组合：中期结果来自第3期，随机，双盲，安慰剂对照试验
3. Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) [J] . Fraser Graeme, Chanan-Khan Asher, Demirkan Faith, Leukemia and lymphoma . 2020,第S1期

机译：最终5年的更新结果来自Ibrutinib Plus Bendamustine和Rituximab（Br）的第3阶段研究（Helios），患有复发/难治性慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）
4. Efficiency and Toxmcity of the Fludarabine and Cyclo- Phosphamide Combined Therapy in Relapsed/ Resistant Patients with B-cell Chronic Lymphocytic Leukaemia (CLL)-Polish Multicenter Study [C] . M. Kowal, A. Dmoszynska, D. Jawniak, European Haematology Association . 2002

机译：B-Cell慢性淋巴细胞白血病（CLL） - 渗透多中心研究的复发/抗性患者复发/抗性患者的氟氮胺碱和环磷酰胺联合治疗的效率和毒性
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized Double-blind Placebo-Controlled Trial [O] . Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R. Brown, -1

机译：复发/难治性CLL患者的依达拉西布或安慰剂联合苯达莫司汀和利妥昔单抗-3期随机双盲安慰剂对照试验的中期结果
7. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial [O] . Zelenetz, Andrew D., Barrientos, Jacqueline C., Brown, Jennifer R., 2017

机译：Idelalisib或安慰剂与苯达莫司汀和利妥昔单抗联合用于复发或难治性慢性淋巴细胞白血病患者：3期随机，双盲，安慰剂对照试验的中期结果

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

著录项

相似文献

相关主题

期刊订阅